Key Takeaways
- A deliberate revenue reset, now complete: Revenue fell to INR1,300 crores in FY24 as management sacrificed low-margin sales to restore discipline, a course-correction it calls an aberration and believes is now behind it.
- Gross margin snapped back ~10pp in Q4: The recovery toward historical highs of ~50%-51% was driven by rationing unprofitable sales and leveraging legacy customer relationships, not by market pricing improvements.
- A large, prudent COVID inventory provision: Approximately INR120 crores was provided for COVID-era inventory because the WHO no longer classifies COVID as a pandemic, restricting the freedom to operate under voluntary licenses.
- FY25 guidance reaffirmed despite a one-quarter delay: Management targets revenue of ~INR1,500 crores and an EBITDA run rate of INR260-INR290 crores, with an exit run rate of almost INR80 crores.
- What to watch next quarter: Whether the rights issue closes smoothly and delivers the promised debt reduction, the pace of gross margin improvement toward the 50%-51% target, and any update on the INR50-crore insurance claim.
The FY24 Reset: Sacrificing Revenue for Discipline
- Revenue was deliberately walked away from: FY24 revenue of INR1,300 crores was an aberration caused by H2 actions where the company chose to sacrifice revenue to restore discipline in its business approach, a correction management now considers complete.
- Ibuprofen business corrected: The company had expanded into unregulated markets and domestic business via incremental ibuprofen capacity, which caused problems. This was corrected by taking off all low-margin sales and returning focus to regulated markets.
- Gross margin recovery mechanism: The nearly 10-percentage-point Q4 improvement came from course-correcting selling behaviour, specifically rationing low-margin sales, and leveraging long-standing legacy customer relationships. Market pricing did not improve.
- No more exceptional items: Management stated there are no more exceptional items on the balance sheet that investors need to worry about, drawing a line under the provisioning cycle.
Arun Kumar: "I'm very confident that Solara will hit its historical highs of its EBITDA in the next 6 to 8 quarters, and we will meet our guidance, which we are reaffirming again today in spite of the 1quarter delay that we had originally expected."
COVID Inventory Provisioning
- A prudent INR120-crore provision taken: The WHO no longer classifies COVID as a pandemic, which restricts the company's freedom to operate under voluntary licenses. The inventory has a long shelf life but cannot be sold until patents expire, so management provisioned it to remove the overhang from operating performance.
- No timeline for monetization: Management will update investors on progress but gave no specific timeline for when the COVID inventory might become sellable, making this a contingent asset with an uncertain trigger.
Arun Kumar: "We took a prudent decision to take a provisioning of this inventory such that the focus for this financial year and going forward would purely be based on an operating leverage the company is focused on."
Vizag Plant: Retrofit and FDA Outcome
- Clean FDA inspection supports retrofit plans: The FDA inspection of the Vizag plant resulted in a zero-483 outcome, clearing the way for the planned retrofit.
- Retrofit to move beyond ibuprofen: The plant will be retrofitted to manufacture multipurpose products, addressing a glut of ibuprofen capacity. All activities are expected to be completed in FY25, after which the additional capacity of close to about 1,000 kilolitres will be available for growth.
- Cost reduction already underway: Actions include right-sizing the Vizag facility for extended capacity utilization and being more cost-competitive across operations. The INR15 crores per quarter run rate adjustment is already achieved.
- Revenue potential without new capex: On the current asset base, revenues can reach close to about INR2,500 crores, depending on product mix, once the retrofit is complete and capacity is deployed.
Balance Sheet & Rights Issue
- Partly paid rights issue to reduce debt: A partly paid rights issue was announced to support balance sheet actions and significantly reduce debt. It opened and closes on June 11, 2024. Promoters are participating and intend to upsize entitlements.
- Structure questioned by an analyst: An analyst asked why a partly paid structure was chosen over a full-amount rights issue, noting that a full amount would have reduced debt directly by INR350-INR400 crores and saved interest costs. Management answered that the general consensus from advisers was that a partly paid rights is more practical in these circumstances.
- Insurance claim in process: A claim of around INR50 crores has been made for losses in Puducherry. The process is ongoing, with a first ad-hoc amount of INR10 crores expected in about a month.
- Cash flow expected to match or beat EBITDA: Excess non-COVID inventory of over INR100 crores will be used within FY25, improving cash flow. Management expects cash flow to be as good as EBITDA or even better due to focus on inventory liquidation, free cash generation, and cash-to-cash cycle reduction.
New Products and the Growth Path
- New products to contribute meaningfully in FY25: New product introductions are expected to contribute approximately INR150 crores to INR200 crores of the INR1,500-crore FY25 guidance.
- Management declined to name specific products: When asked for colour on new products and new orders, management declined to disclose specifics, citing confidentiality and that it is not the norm to disclose them on earnings calls.
- Long-term growth ambition: Management is looking at 15% to 18% top-line CAGR after FY25, with the Vizag facility retrofitted for multipurpose products providing the capacity headroom.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY25 revenue | Approximately INR1,500 crores | FY25 |
| FY25 EBITDA run rate | INR260 crores to INR290 crores | FY25 |
| FY25 EBITDA exit run rate | Almost INR80 crores | Q4 FY25 exit |
| Gross margin recovery | Achieve historical levels of ~50%-51% | During FY25 |
| EBITDA return to historical highs | Hit historical highs of EBITDA | Next 6 to 8 quarters |
| Vizag retrofit completion | All activities completed, ~1,000 KL capacity available | FY25 |
| Non-COVID excess inventory liquidation | Over INR100 crores used, improving cash flow | Within FY25 |
| Insurance claim (Puducherry) | First ad-hoc amount of INR10 crores received | ~1 month |
| Long-term revenue CAGR | 15% to 18% top-line CAGR | After FY25 |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue | ₹1,300 cr (FY24 full year); FY25 guidance of approx. ₹1,500 cr |
| Gross margin | Moved almost 10 percentage points QoQ, approaching historical highs of 50%-51% |
| Reported EBITDA | ₹11 cr |
| Adjusted EBITDA | Nearly ₹38 cr |
| EBITDA guidance (FY25) | ₹260 cr to ₹290 cr run rate, with exit run rate of almost ₹80 cr |
| COVID inventory provision | Approx. ₹120-odd cr provisioned in Q4 |
| Revenue growth target (FY25) | 15%-16% (implied from ₹1,300 cr to ₹1,500 cr) |
| Long-term revenue CAGR target (post FY25) | 15% to 18% |
| Regulated market sales share | 75% of sales |
| New product contribution (FY25) | Approx. ₹150 cr to ₹200 cr of ₹1,500 cr guidance |
| Ibuprofen contribution to sales | About ₹500-₹600 cr |
| Cost reduction program (full year) | ₹60 cr to ₹75 cr base cost reduction from previous year |
| Quarterly cost run rate reduction | ₹15 cr per quarter |
| US DMFs filed | Close to 95 |
| US DMFs commercialized | Roughly 25 to 30 |
| Insurance claim (Puducherry incident) | Around ₹50 cr claimed; first adhoc amount of ₹10 cr expected |
| Potential revenue on current asset base | Close to about ₹2,500 cr without new large capex |